Chlamydia pneumoniae is a human respiratory pathogen that is prone to treatment failures. The primary reason for this is the bacterium's propensity to confer into a dormant, metabolically altered state known as persistence. In this project, we aim to find new treatment strategies to improve the sensitivity of chlamydial infections to antibiotics. The work focuses on identification of chemosensitizing small molecules and studying their molecular targets.